<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03090165</url>
  </required_header>
  <id_info>
    <org_study_id>BTCRC BRE15-024</org_study_id>
    <nct_id>NCT03090165</nct_id>
  </id_info>
  <brief_title>Ribociclib and Bicalutamide in AR+ TNBC</brief_title>
  <official_title>A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combination With Bicalutamide, an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-negative Breast Cancer: Big Ten Cancer Research Consortium BRE15-024</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kari Wisinski</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Big Ten Cancer Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Big Ten Cancer Research Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multi-institutional, single arm phase II trial of ribociclib in&#xD;
      combination with bicalutamide in advanced AR+ triple-negative breast cancer. No randomization&#xD;
      or blinding is involved.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2, 2017</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Maximum Tolerated Dose</measure>
    <time_frame>D1 of treatment to end of cohort cycle (assessed at 28 days)</time_frame>
    <description>Phase I: Maximum tolerated dose (MTD) for subjects receiving ribociclib and bicalutamide without experiencing dose-limiting toxicity(s) (DLT) per Common Terminology Criteria for Adverse Events (CTCAE) v4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Clinical benefit rate (CBR) of treatment combination</measure>
    <time_frame>D1 of treatment to end of 4 treatment cycles (assessed at 16 weeks)</time_frame>
    <description>Compare sum of confirmed complete plus partial responses plus stable disease per response evaluation criteria in solid tumors (RECIST) 1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: Objective Response Rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>The objective response rate is the proportion of all subjects with confirmed PR or CR according to RECIST 1.1, from the start of treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the start of treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Duration of Response</measure>
    <time_frame>2 years</time_frame>
    <description>Duration of overall response-the period measured from the time that measurement criteria are met for complete or partial response (whichever status is recorded first) until the date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since treatment started).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Assess Safety and Tolerability By summarizing counts and percentages grade 3-5 adverse events (NCI CTCAE Version 4)</measure>
    <time_frame>2 years</time_frame>
    <description>By summarizing counts and percentages grade 3-5 adverse events (NCI CTCAE Version 4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Ribociclib pharmacokinetics</measure>
    <time_frame>2 months</time_frame>
    <description>Time points: Peak Plasma Concentration (Cmax) Pre dose and 2-hours post-dose (±15 min) pharmacokinetic samples will be collected on Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 2 Day 15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Progression Free Survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>PFS will be summarized using Kaplan-Meier estimates of the median survival times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Objective Response Rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>by RECIST 1.1 on treatment with combination of bicalutamide and ribociclib in advanced AR+ TNBC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Overall Survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival is defined by the date of treatment initiation to date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Estimate Duration of Response</measure>
    <time_frame>2 years</time_frame>
    <description>On treatment with combination of bicalutamide and ribociclib in advanced Androgen Receptor (AR)+ Triple Negative Breast Cancer (TNBC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Evaluate Safety and Tolerability By summarizing counts and percentages grade 3-5 adverse events (NCI CTCAE Version 4)</measure>
    <time_frame>2 years</time_frame>
    <description>By summarizing counts and percentages grade 3-5 adverse events (NCI CTCAE Version 4)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A - Phase I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation Cohort 1 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 400mg PO daily on days 1-21 of a 28 day cycle.&#xD;
Cohort 2 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 400mg PO daily on days 1-28 of a 28 day cycle.&#xD;
Cohort 3 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 600mg PO daily on days 1-21 of a 28 day cycle.&#xD;
Experimental: Arm B - Phase II Investigational Treatment The maximum safe dose of ribociclib in combination with bicalutamide will be given to up to 25 patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribociclib</intervention_name>
    <description>400mg PO</description>
    <arm_group_label>Arm A - Phase I</arm_group_label>
    <other_name>LEE011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribociclib</intervention_name>
    <description>600mg PO</description>
    <arm_group_label>Arm A - Phase I</arm_group_label>
    <other_name>LEE011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide</intervention_name>
    <description>150mg PO</description>
    <arm_group_label>Arm A - Phase I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Androgen Receptor (AR) positivity definitions -Phase I: Metastatic or unresectable AR+&#xD;
        triple-negative breast cancer (TNBC); AR positivity defined as IHC staining of &gt;0% of tumor&#xD;
        nuclei.&#xD;
&#xD;
        OR&#xD;
&#xD;
        -Phase II: Metastatic or unresectable AR+ triple-negative breast cancer (TNBC); AR&#xD;
        positivity defined as IHC staining of ≥10% of tumor nuclei.&#xD;
&#xD;
        Inclusion Criteria for Phase I and II study.&#xD;
&#xD;
        In addition to being AR positive as defined in protocol, subjects must also meet all of the&#xD;
        following applicable inclusion criteria.&#xD;
&#xD;
          -  Histological or cytological confirmed, metastatic or unresectable triple-negative&#xD;
             breast cancer (TNBC). TNBC will be defined as expression of ER&lt;10%, PR&lt; 10% and HER2&#xD;
             negative either by IHC (0, 1+ are negative, 2+ equivocal) or in situ hybridization&#xD;
             method (ratio &lt;2.0 is negative).&#xD;
&#xD;
          -  Written informed consent and HIPAA authorization for release of personal health&#xD;
             information. NOTE: HIPAA authorization may be included in the informed consent or&#xD;
             obtained separately.&#xD;
&#xD;
          -  Up to 1 prior line of systemic therapy for metastatic disease is allowed. Combination&#xD;
             therapy will be considered 1 line.&#xD;
&#xD;
          -  Age ≥ 18 years at the time of consent.&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1 within 28 days prior to registration.&#xD;
&#xD;
          -  Life expectancy of &gt; 12 weeks as determined by the treating physician.&#xD;
&#xD;
          -  Measurable disease according to RECIST 1.1 within 28 days prior to registration.&#xD;
&#xD;
          -  No active central nervous system (CNS) metastatic disease. NOTE: Subjects with CNS&#xD;
             involvement must meet ALL of the following to be eligible:&#xD;
&#xD;
               -  At least 28 days from prior definitive treatment of their CNS disease by surgical&#xD;
                  resection, stereotactic body radiation therapy (SBRT) or whole brain radiation&#xD;
                  treatment (WBRT) at the time of registration&#xD;
&#xD;
               -  AND asymptomatic and off systemic corticosteroids and/or enzyme-inducing&#xD;
                  anti-epileptic medications for brain metastases for &gt;14 days prior to&#xD;
                  registration.&#xD;
&#xD;
          -  Prior cancer treatment must be completed at least 14 days prior to registration and&#xD;
             the subject must have recovered from all reversible acute toxic effects of the regimen&#xD;
             (other than alopecia) to ≤grade 1 or to baseline prior to initiation of that therapy.&#xD;
&#xD;
          -  Screening rate-corrected QT interval (QTc) must be &lt;450msec and a resting heart rate&#xD;
             of at least 50-90 bpm via a standard 12-lead ECG within 28 days prior to registration.&#xD;
&#xD;
          -  Demonstrate adequate bone marrow and organ function as defined in the protocol; all&#xD;
             screening labs to be obtained within 28 days prior to registration.&#xD;
&#xD;
          -  Females of childbearing potential must have a negative serum pregnancy test within 7&#xD;
             days prior to registration. NOTE: Females are considered of child bearing potential&#xD;
             unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal&#xD;
             ligation, or bilateral oophorectomy), or they are naturally postmenopausal for at&#xD;
             least 12 consecutive months, or her male partner has had a vasectomy at least 6 months&#xD;
             prior to screening (The sterilized male partner must be her only sexual partner.).&#xD;
&#xD;
          -  Females of childbearing potential and males must be willing to abstain from&#xD;
             heterosexual activity or must agree to use adequate contraception (hormonal or barrier&#xD;
             method) for the duration of study participation and for 3 weeks after discontinuation&#xD;
             of study treatment.&#xD;
&#xD;
          -  As determined by the enrolling physician or protocol designee, ability of the subject&#xD;
             to understand and comply with study procedures for the entire length of the study.&#xD;
&#xD;
          -  Able to swallow bicalutamide and ribociclib capsules/tablets.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with AR antagonists including but not limited to bicalutamide,&#xD;
             enzalutamide, abiraterone and orteronel.&#xD;
&#xD;
          -  Prior therapy with any CDK 4/6 inhibitors with the exception of participation in a&#xD;
             window or preoperative study for Stage I-III operable breast cancer..&#xD;
&#xD;
          -  Active infection requiring systemic therapy.&#xD;
&#xD;
          -  Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the&#xD;
             mother is being treated on study).&#xD;
&#xD;
          -  Known additional malignancy that is active and/or progressive requiring treatment;&#xD;
             exceptions include basal cell or squamous cell skin cancer, in situ cervical or&#xD;
             bladder cancer, or other cancer for which the subject has been disease-free for at&#xD;
             least three years.&#xD;
&#xD;
          -  Treatment with any investigational drug within 14 days prior to registration or within&#xD;
             5 half-lives of the investigational product, whichever is longer. Immunotherapies such&#xD;
             as PD-L1 or PD-1 inhibitors only require a 14 day window, regardless of half-life.&#xD;
&#xD;
          -  Subject who has received radiotherapy &lt;14 days prior to registration, and who has not&#xD;
             recovered to grade 1 or better from related side effects of such therapy (exceptions&#xD;
             include alopecia and any adverse events deemed by the investigator to be unlikely to&#xD;
             interfere with the study drug safety).&#xD;
&#xD;
          -  Subject has had major surgery within 14 days prior to registration or has not&#xD;
             recovered from major side effects of the surgery (tumor biopsy is not considered as&#xD;
             major surgery).&#xD;
&#xD;
          -  Known hypersensitivity to any of the excipients of ribociclib or bicalutamide.&#xD;
&#xD;
          -  Any impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled&#xD;
             nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).&#xD;
&#xD;
          -  Known history of HIV infection (testing not mandatory).&#xD;
&#xD;
          -  Any concurrent severe and/or uncontrolled medical condition that would, in the&#xD;
             investigator's judgment, cause unacceptable safety risks, contraindicate subject&#xD;
             participation in the clinical study or compromise compliance with the protocol (e.g.&#xD;
             chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled&#xD;
             fungal, bacterial or viral infections, etc.).&#xD;
&#xD;
          -  Subjects with any of the following conditions are excluded:&#xD;
&#xD;
               -  Serious or non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
               -  History of abdominal fistula, gastrointestinal perforation, or intra- abdominal&#xD;
                  abscess within 28 days prior to registration.&#xD;
&#xD;
               -  Any history of cerebrovascular accident (CVA) or transient ischemic attack within&#xD;
                  12 months prior to registration.&#xD;
&#xD;
               -  Any history of arterial or venous thrombosis/thromboembolic event, including&#xD;
                  pulmonary embolism within the past 12 months prior to registration.&#xD;
&#xD;
               -  History of acute coronary syndromes (including myocardial infarction, unstable&#xD;
                  angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or&#xD;
                  symptomatic pericarditis within 6 months prior to registration.&#xD;
&#xD;
               -  Symptomatic congestive heart failure (New York Heart Association III-IV) or&#xD;
                  documented current cardiomyopathy with left ventricular ejection fraction (LVEF)&#xD;
                  &lt;50%&#xD;
&#xD;
               -  Clinically significant cardiac arrhythmias (e.g. ventricular tachycardia) or&#xD;
                  clinically significant, complete left bundle branch block, high-grade AV block&#xD;
                  (e.g. bifascicular block, Mobitz type II and third-degree AV block).&#xD;
&#xD;
               -  Any episode of atrial fibrillation in the prior 12 months.&#xD;
&#xD;
               -  Long QT syndrome or family history of idiopathic sudden death or congenital long&#xD;
                  QT syndrome.&#xD;
&#xD;
               -  Concomitant use of medication(s) with a known risk to prolong the QT interval&#xD;
                  and/or known to cause Torsades de Pointe that cannot be discontinued (within 5&#xD;
                  half-lives or 7 days prior to starting study drug) or replaced by safe&#xD;
                  alternative medication. See ManualDocuments/Info tab of the EDC for list of&#xD;
                  medications.&#xD;
&#xD;
               -  Systolic blood pressure (SBP) &gt;160 mmHg or &lt;90 mmHg at screening.&#xD;
&#xD;
          -  Currently receiving any known strong inducers or inhibitors of CYP3A4/5 which cannot&#xD;
             be discontinued 7 days prior to starting study drug (see Appendix 1 for details).&#xD;
&#xD;
          -  Subject is currently receiving or has received systemic corticosteroids &lt;14 days prior&#xD;
             to starting study drugs. The following uses of corticosteroids are permitted: a short&#xD;
             duration (&lt;5 days) of systemic corticosteroidssingle doses, any duration of topical&#xD;
             applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways&#xD;
             diseases), eye drops or local injections (e.g., intra-articular).&#xD;
&#xD;
          -  Subject is currently receiving warfarin or other coumarin-derived anticoagulant for&#xD;
             treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight&#xD;
             heparin (LMWH), novel oral anticoagulants (NOACs) or fondaparinux is allowed.&#xD;
&#xD;
          -  In subjects with a diagnosis of cirrhosis, sSubjects with a Child-Pugh score B or C&#xD;
             are excluded. Please see chart in the ManualDocuments/Info tab of the electronic data&#xD;
             capture system (EDC) for Child-Pugh score calculation. If subject does not have&#xD;
             diagnosed or suspected cirrhosis, the Child-Pugh score does not need to be calculated.&#xD;
&#xD;
          -  Subjects taking herbal supplements (St. John's Wort, gingko balboa, etc.) must&#xD;
             discontinue these supplements 14 days prior to study registration.&#xD;
&#xD;
          -  Consumption of grapefruit, grapefruit hybrids, pummelos, star-fruit, Seville oranges&#xD;
             or products containing the juice of each within 7 days prior to study registration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kari Wisinski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Cancer Institute</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bigtencrc.org/</url>
    <description>Big Ten Cancer Research Consortium Website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 1, 2017</study_first_submitted>
  <study_first_submitted_qc>March 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Big Ten Cancer Research Consortium</investigator_affiliation>
    <investigator_full_name>Kari Wisinski</investigator_full_name>
    <investigator_title>Sponsor Investigator</investigator_title>
  </responsible_party>
  <keyword>Triple Negative Breast Neoplasms</keyword>
  <keyword>ribociclib</keyword>
  <keyword>LEE011</keyword>
  <keyword>CDK 4/6 inhibitor</keyword>
  <keyword>bicalutamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

